Dr. Kazmi on Tailoring Treatment to Various Subtypes of CRC

Video

Syed Kazmi, MD, discusses the importance of tailoring treatment to different subtypes of colorectal cancer.

Syed Kazmi, MD, an oncologist at The University of Texas Southwestern Medical Center, discusses the importance of tailoring treatment to different subtypes of colorectal cancer (CRC).

CRC is no longer considered a homogeneous disease, says Kazmi. Instead, the disease is characterized by alterations in BRAF, HER2, NTRK, and others, Kazmi explains. Moreover, the various subtypes require tailored treatment approaches, Kazmi adds.

For example, patients with microsatellite instability–high CRC are treated with immunotherapy in the first- or later-line settings, Kazmi says. Although molecular profiling information should be available for all patients with newly diagnosed stage IV CRC, it is even more critical to understand the molecular subtype of patients who progress on frontline therapy, concludes Kazmi.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD